{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-154016","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.225708+00:00","generated_at":"2026-05-18T10:27:02.291304+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026","bullets":["IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.","ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.","Primary endpoint: mean percentage change from baseline in EASI score at Week 20.","Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.","Dose-finding study designed to guide optimal dosing for future Phase 3 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-154016","json":"https://secwatch.observer/filing/0001193125-25-154016.json","markdown":"https://secwatch.observer/filing/0001193125-25-154016.md","text":"https://secwatch.observer/filing/0001193125-25-154016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/0001193125-25-154016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312525154016/d917926d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:27:02.291304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}